Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer

Researchers demonstrated that under enzalutamide treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affected surrounding prostate cancer cells, promoting tumor cell proliferation and anti-androgen resistance.